Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …

ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …

Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse
effects of drug therapies. The majority of hepatically cleared drugs are metabolized by …

It has been nearly 9years since the FDA (Food and Drug Administration) approved the first
anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other …

Summary Background The Memorial Sloan Kettering Cancer Center (MSKCC) risk model is
an established prognostic tool for metastatic renal-cell carcinoma that integrates clinical and …

Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …

Background: Little is known on factors predicting sunitinib toxicity. Recently, the condition of
low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in …

The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced
stage solid tumors has become the standard of care in several instances, particularly for …

The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect
to drug effects. In some cases, there may be extensive evidence of variants that have known …